|
|
|
Insider
Information: |
Torley Helen |
Relationship: |
Director |
City: |
South San Francisco |
State: |
CA |
|
|
Insider
Summary: |
|
|
|
Companies Owned : |
4 |
|
Direct
Shares |
683,004 |
|
Indirect Shares
|
0 |
|
|
Direct
Value |
$30,539,335 |
|
|
Indirect Value
|
$0 |
|
|
Total
Shares |
683,004 |
|
|
Total
Value |
$30,539,335 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
Total
Filings :
|
0
|
2
|
Stock
price went up :
|
0
|
0
|
Stock
price went down : |
0
|
2
|
|
|
|
Gain/Loss Ratio : |
0.0
|
-2.0
|
Percentage
Gain/Loss : |
0.0%
|
-28.8%
|
|
|
|
|
|
|
Holdings
:
Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold |
|
Onyx Pharmaceuticals Inc |
ONXX |
EVP, Chief Commercial ... |
2013-10-01 |
0 |
2011-08-29 |
0 |
Premium* |
|
Halozyme Therapeutics Inc |
HALO |
|
2024-02-16 |
676,744 |
2014-09-16 |
0 |
Premium* |
|
Relypsa Inc |
RLYP |
Director |
2016-09-01 |
0 |
2015-06-04 |
0 |
Premium* |
|
Quest Diagnostics Inc |
DGX |
Director |
2021-05-25 |
6,260 |
2018-05-15 |
0 |
Premium* |
|
|
|
|
|
|
|
|
|
|
Records found :
169 |
Free Registration Required For Full Results. Limit: 25
|
|
Download |
Page 4 of 7
|
Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
HALO |
Halozyme Therapeutics Inc |
President and CEO |
|
2020-02-22 |
4 |
D |
$21.83 |
$425,925 |
D/D |
(19,511) |
490,522 |
0 |
- |
|
HALO |
Halozyme Therapeutics Inc |
President and CEO |
|
2021-02-10 |
4 |
D |
$50.60 |
$784,755 |
D/D |
(15,509) |
486,295 |
0 |
- |
|
HALO |
Halozyme Therapeutics Inc |
President and CEO |
|
2021-02-12 |
4 |
D |
$49.84 |
$810,349 |
D/D |
(16,259) |
502,831 |
0 |
- |
|
HALO |
Halozyme Therapeutics Inc |
President and CEO |
|
2021-02-14 |
4 |
D |
$49.84 |
$709,871 |
D/D |
(14,243) |
517,317 |
0 |
- |
|
HALO |
Halozyme Therapeutics Inc |
President and CEO |
|
2021-02-22 |
4 |
D |
$48.69 |
$949,991 |
D/D |
(19,511) |
537,160 |
0 |
- |
|
HALO |
Halozyme Therapeutics Inc |
President and CEO |
|
2022-02-10 |
4 |
D |
$34.94 |
$579,934 |
D/D |
(16,598) |
551,844 |
0 |
- |
|
HALO |
Halozyme Therapeutics Inc |
President and CEO |
|
2022-02-12 |
4 |
D |
$34.20 |
$590,497 |
D/D |
(17,266) |
567,373 |
0 |
- |
|
HALO |
Halozyme Therapeutics Inc |
President and CEO |
|
2022-02-14 |
4 |
D |
$33.64 |
$508,805 |
D/D |
(15,125) |
580,977 |
0 |
- |
|
HALO |
Halozyme Therapeutics Inc |
President and CEO |
|
2022-02-15 |
4 |
D |
$34.43 |
$237,292 |
D/D |
(6,892) |
587,177 |
0 |
- |
|
HALO |
Halozyme Therapeutics Inc |
PRESIDENT AND CEO |
|
2023-02-10 |
4 |
D |
$48.92 |
$805,663 |
D/D |
(16,469) |
601,989 |
0 |
- |
|
HALO |
Halozyme Therapeutics Inc |
PRESIDENT AND CEO |
|
2023-02-12 |
4 |
D |
$48.92 |
$844,653 |
D/D |
(17,266) |
617,517 |
0 |
- |
|
HALO |
Halozyme Therapeutics Inc |
PRESIDENT AND CEO |
|
2023-02-15 |
4 |
D |
$49.20 |
$339,086 |
D/D |
(6,892) |
623,717 |
0 |
- |
|
HALO |
Halozyme Therapeutics Inc |
PRESIDENT AND CEO |
|
2024-02-10 |
4 |
D |
$35.49 |
$601,307 |
D/D |
(16,943) |
638,004 |
0 |
- |
|
HALO |
Halozyme Therapeutics Inc |
PRESIDENT AND CEO |
|
2024-02-15 |
4 |
D |
$35.91 |
$885,361 |
D/D |
(24,655) |
659,222 |
0 |
- |
|
HALO |
Halozyme Therapeutics Inc |
PRESIDENT AND CEO |
|
2024-02-16 |
4 |
D |
$36.10 |
$735,068 |
D/D |
(20,362) |
676,744 |
0 |
- |
|
HALO |
Halozyme Therapeutics Inc |
President and CEO |
|
2020-08-14 |
4 |
GD |
$0.00 |
$0 |
D/D |
10,000 |
480,522 |
0 |
- |
|
HALO |
Halozyme Therapeutics Inc |
President and CEO |
|
2020-11-30 |
4 |
GD |
$0.00 |
$0 |
D/D |
10,000 |
470,522 |
0 |
- |
|
HALO |
Halozyme Therapeutics Inc |
PRESIDENT AND CEO |
|
2023-03-01 |
4 |
GD |
$0.00 |
$0 |
D/D |
10,000 |
623,666 |
0 |
- |
|
ONXX |
Onyx Pharmaceuticals Inc |
EVP, Chief Commercial Officer |
|
2012-11-12 |
4 |
OE |
$33.70 |
$283,000 |
D/D |
8,250 |
51,509 |
0 |
- |
|
ONXX |
Onyx Pharmaceuticals Inc |
EVP, Chief Commercial Officer |
|
2013-02-04 |
4 |
OE |
$33.70 |
$283,000 |
D/D |
8,250 |
47,762 |
0 |
- |
|
ONXX |
Onyx Pharmaceuticals Inc |
EVP, Chief Commercial Officer |
|
2013-05-13 |
4 |
OE |
$33.70 |
$283,000 |
D/D |
8,250 |
55,896 |
0 |
- |
|
ONXX |
Onyx Pharmaceuticals Inc |
EVP, Chief Commercial Officer |
|
2013-08-12 |
4 |
OE |
$33.70 |
$283,000 |
D/D |
8,250 |
55,896 |
0 |
- |
|
HALO |
Halozyme Therapeutics Inc |
President and CEO |
|
2015-01-06 |
4 |
OE |
$0.00 |
$0 |
D/D |
30,000 |
80,000 |
0 |
- |
|
HALO |
Halozyme Therapeutics Inc |
President and CEO |
|
2016-01-06 |
4 |
OE |
$0.00 |
$0 |
D/D |
30,000 |
113,145 |
0 |
- |
|
HALO |
Halozyme Therapeutics Inc |
President and CEO |
|
2016-02-06 |
4 |
OE |
$0.00 |
$0 |
D/D |
31,250 |
132,709 |
0 |
- |
|
169 Records found
|
|
Page 4 of 7 |
|
Free Registration Required For Full Results. Limit: 25
|
|
|
Transaction Code Key: |
Ownership Code Key |
|
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
|
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
|
IO |
- Initital Ownership |
D |
- Disposed |
|
|
|
|
|
|